|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.IR |
First Approval Date01 Feb 2018 |
Bioequivalence Study of amlodipine valsartan 10/160 mg manufactured by Alborz Darou and Exforge manufactured by Novartis in 24 Healthy Volunteers
A cross over bioequivalence study of losartan H 50/12.5 mg tablet compared to Hyzaar 50/12.5 mg tablet manufactured by Merck in 24 healthy volunteers under fasting condition
Efficacy of the therapeutic dose of Alborz Darou Enoxaparin in comparison with Clexane: a randomized, open-label non-inferiority trial
100 Clinical Results associated with Alborz Darou Pharmaceutical Co.
0 Patents (Medical) associated with Alborz Darou Pharmaceutical Co.
100 Deals associated with Alborz Darou Pharmaceutical Co.
100 Translational Medicine associated with Alborz Darou Pharmaceutical Co.